01/07/2026
🌿 INVESTMENT OPPORTUNITY | MedTech Industry (Medical Cannabis) | 20% Equity for approx. EUR 2.02M
Are you looking to enter one of the fastest-growing pharmaceutical sectors in Europe? We are offering a 20% equity stake in Panaceum Cannmed Sp. z o.o. for EUR 2,024,000 (total company valuation stands at EUR 11,905,000). The company is currently constructing a state-of-the-art Polish manufacturing center for the pharmaceutical raw material Cannabis flos in Częstochowa. The goal is to challenge foreign corporations and fill a market gap – Poland is currently 100% dependent on imports, and the market is projected to grow from approx. EUR 71.4M to over EUR 238M by 2030.
________________________________________
📈 Why Invest in Panaceum Cannmed?
• Proven Market Credibility: The company is currently undergoing rigorous public verification by running a loan pre-campaign (target: EUR 2.38M) on the KNF-licensed (Polish Financial Supervision Authority) platform: https://inwestycje.finansowo.pl/oferty/nadchodzace/panaceum-cannmed. Over 40 investors have already pledged their first millions there.
• Secured Hard Assets: This project is not just a "paper promise." The company holds a share capital of over EUR 405,000 and real estate assets in Częstochowa (cultivation hall and manufacturing facility) valued at EUR 1,471,000 by a certified asset appraiser from the PKO BP bank list.
• Buyer Secured Before Launch: A Letter of Intent (LOI) has already been signed with Pharma Vitae Sp. z o.o. for the off-take of the raw material, guaranteeing immediate sales as soon as production starts.
• Unique Model with 3 Revenue Streams:
1. Own GMP pharmaceutical production in cooperation with a Scientific Institute (a state institution ensuring full regulatory stability).
2. Import of lower-cost GACP raw material from global markets (Asia/Europe) and high-margin processing to medical GMP standards under our own certificate (production line capacity reaches up to 2,000 kg/month).
3. B2B services for external entities – contract packaging and testing in our own advanced physicochemical laboratory (HPLC, ICP-MS).
• World-Class Team: The CEO is production engineer Konrad Palka. The role of Qualified Person (QP), critical in the pharmaceutical regulatory regime, has been assumed by Anna Krawczak – an expert with over 30 years of industry experience (ex-Polfa Tarchomin, Bioton).
________________________________________
📊 Financial Projections (According to the Company's Business Plan):
• 2027 (Commercial Launch): EUR 5.36M gross revenue.
• 2028 (Scaling & Export to DE/UK): EUR 21.83M gross revenue and a projected FCFE of +EUR 1.98M.
• 2029+ (Full Scale): EUR 27.14M annual revenue.
________________________________________
🤝 Use of Proceeds & Target Audience:
The funds of EUR 2,024,000 will be allocated directly toward completing Class D cleanrooms, automating production lines, equipping the laboratory, and obtaining final GMP certificates and permits from the Chief Pharmaceutical Inspectorate (GIF).
This offer to acquire 20% equity is tailored for Venture Capital funds, Private Equity funds, strategic industry partners, or high-net-worth individual investors (Business Angels).
📩 If interested, we invite you to contact us via Direct Message (DM). We will gladly share the full Investment Teaser, business plan, property appraisal, and detailed financial statements.
________________________________________
